Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
J Cancer Res Clin Oncol. 2020 Oct;146(10):2717-2718. doi: 10.1007/s00432-020-03275-x. Epub 2020 May 30.
COVID-19 is causing a lot of problems in health services around the world, especially in medical institutions receiving cancer patients. On March 12, China's National Health Commission announced that the peak of the COVID-19 epidemic has passed in China. Thus, a proper arrangement of medication, surgery and radiotherapy for patients with cancer is of vital importance after the epidemic peak.
A range of measures have been implemented in our center. Specific patients take priority for chemotherapy treatment. The amount of semi-elective and elective surgeries could be gradually increased beyond urgent and emergency surgery. The hypofractionated radiotherapy is recommended in the right circumstances.
On March 13, our center announced that more than 5000 visits of chemotherapy and radiotherapy are arranged in our outpatient clinics and none of our patients and staffs have been diagnosed with COVID-19 as of March 28, 2020.
The rational arrangement we make now may be helpful to the future restoration of cancer treatments in other countries.
COVID-19 正在给全球卫生服务带来诸多问题,尤其是在接收癌症患者的医疗机构。2020 年 3 月 12 日,中国国家卫生健康委员会宣布中国 COVID-19 疫情流行高峰已经过去。因此,在疫情高峰过后,合理安排癌症患者的药物治疗、手术和放疗至关重要。
我们中心采取了一系列措施。特定患者优先进行化疗治疗。在紧急和急诊手术之外,半选择性和选择性手术的数量可以逐渐增加。在适当的情况下推荐采用分次放疗。
2020 年 3 月 13 日,我们中心宣布在我们的门诊部安排了超过 5000 次的化疗和放疗就诊,截至 2020 年 3 月 28 日,我们没有任何患者和员工被诊断出 COVID-19。
我们现在的合理安排可能有助于其他国家未来恢复癌症治疗。